K
Keyue Ding
Researcher at Queen's University
Publications - 116
Citations - 10131
Keyue Ding is an academic researcher from Queen's University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 30, co-authored 103 publications receiving 9147 citations. Previous affiliations of Keyue Ding include University of Toronto & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Ming-Sound Tsao,Akira Sakurada,Jean-Claude Cutz,Jean-Claude Cutz,Chang-Qi Zhu,Chang-Qi Zhu,Suzanne Kamel-Reid,Suzanne Kamel-Reid,Jeremy A. Squire,Jeremy A. Squire,Ian A. J. Lorimer,Tong Zhang,Tong Zhang,Ni Liu,Ni Liu,Manijeh Daneshmand,Paula Marrano,Paula Marrano,Gilda da Cunha Santos,Gilda da Cunha Santos,Alain E. Lagarde,Frank C. Richardson,Lesley Seymour,Marlo Whitehead,Keyue Ding,Joseph L. Pater,Frances A. Shepherd,Frances A. Shepherd +27 more
TL;DR: Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.
Journal ArticleDOI
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton,Robert B. Livingston,David H. Johnson,James R. Rigas,Michael R. Johnston,Charles Butts,Yvon Cormier,Glenwood D. Goss,Richard Inculet,Eric Vallières,Willard A Fry,Drew Bethune,Joseph Ayoub,Keyue Ding,Lesley Seymour,Barbara Graham,Ming-Sound Tsao,David R. Gandara,Kenneth A. Kesler,Todd L. Demmy,Frances A. Shepherd +20 more
TL;DR: Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
Journal ArticleDOI
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.
Kerby Shedden,Jeremy M. G. Taylor,Steven A. Enkemann,Ming-Sound Tsao,Timothy J. Yeatman,William L. Gerald,Steven A. Eschrich,Igor Jurisica,Thomas J. Giordano,David E. Misek,Andrew C. Chang,Chang-Qi Zhu,Daniel Strumpf,Samir M. Hanash,Frances A. Shepherd,Keyue Ding,Lesley Seymour,Katsuhiko Naoki,Nathan A. Pennell,Barbara A. Weir,Roeland Verhaak,Christine Ladd-Acosta,Todd R. Golub,Michael Gruidl,Anupama Sharma,Janos Szoke,Maureen F. Zakowski,Valerie W. Rusch,Mark G. Kris,Agnes Viale,Noriko Motoi,William D. Travis,Barbara A. Conley,Venkatraman E. Seshan,Matthew Meyerson,Matthew Meyerson,Rork Kuick,Kevin K. Dobbin,Tracy Lively,James W. Jacobson,David G. Beer +40 more
TL;DR: A large, training–testing, multi-site, blinded validation study to characterize the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas, providing the largest available set of microarray data with extensive pathological and clinical annotation for lungAdenocARCinomas.
Journal ArticleDOI
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
Chang-Qi Zhu,Gilda da Cunha Santos,Keyue Ding,Akira Sakurada,Jean-Claude Cutz,Ni Liu,Tong Zhang,Paula Marrano,Mario Whitehead,Jeremy A. Squire,Suzanne Kamel-Reid,Lesley Seymour,Frances A. Shepherd,Ming-Sound Tsao +13 more
TL;DR: EGFR mutations and high copy number are predictive of response to erlotinib and EGFR FISH is the strongest prognostic marker and a significant predictive marker of differential survival benefit from erlot inib.
Journal ArticleDOI
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
James Perry,Normand Laperriere,Christopher J. O'Callaghan,Alba A. Brandes,Johan Menten,Claire Phillips,Michael Fay,Michael Fay,Ryo Nishikawa,J. Gregory Cairncross,Wilson Roa,David Osoba,John P. Rossiter,Arjun Sahgal,H Hirte,Florence Laigle-Donadey,Enrico Franceschi,Olivier Chinot,Vassilis Golfinopoulos,L. Fariselli,Antje Wick,Loïc Feuvret,Michael Back,Michael Tills,Chad Winch,Brigitta G. Baumert,Wolfgang Wick,Keyue Ding,Warren P. Mason +28 more
TL;DR: In elderly patients with glioblastoma, the addition of temozolomide to short‐course radiotherapy resulted in longer survival than short‐ Course radiotherapy alone.